Meeting
2023 ASCO Annual Meeting
Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.
Authors
Jonathan C. Trent
Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL
Jonathan C. Trent , Robin Lewis Jones , Suzanne George , Hans Gelderblom , Patrick Schöffski , Margaret von Mehren , John Raymond Zalcberg , Yoon-Koo Kang , Albiruni Ryan Abdul Razak , Steven Attia , Axel Le Cesne , William Reichmann , Kam Sprott , Haroun Achour , Matthew L. Sherman , Rodrigo Ruiz-Soto , Jean-Yves Blay , Michael C. Heinrich , Sebastian Bauer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Clinical Trial Registration Number
NCT03673501
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11536)
DOI
10.1200/JCO.2023.41.16_suppl.11536
Abstract #
11536
Poster Bd #
470
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
First Author: Steven Bialick
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Exploration of drug resistance in advanced gastrointestinal stromal tumor.
First Author: Hao Xu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.
First Author: John Raymond Zalcberg
Poster
2023 ASCO Annual Meeting
Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.
First Author: Robin Lewis Jones